Rhythm says NEJM published Phase 3 setmelanotide trial in hypothalamic obesity

The company said the 52-week TRANSCEND study showed a 19.8% placebo-adjusted BMI reduction and clinically meaningful hunger improvements in patients aged 4 and older.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.